The difficulties in determining the difference between antibodies produced by HIV infection and vaccine-induced antibodies were managed by individual vaccine research sites who had special capability to conduct additional laboratory testing on this small pool of vaccine recipients.
[citation needed] At the 2010 International AIDS conference presenters talked about the need for community healthcare providers to understand that if their patients have been in an HIV vaccine trial then their patients are likely to give a false positive HIV test result.
In developing countries with limited access to healthcare, the problems associated with VISP are a special concern.
[citation needed] Researchers from Africa, Asia, North America, and South America have said that getting local government and media support of the research is essential in addition to creating facilities for distinguishing between HIV positive individuals and individuals exhibiting VISP.
[7] VISP is not often a practical concern for other diseases because in most cases good vaccines already exist and most people who have access to healthcare receive them.